State of Alaska Department of Revenue Sells 685 Shares of Moderna, Inc. (NASDAQ:MRNA)

State of Alaska Department of Revenue trimmed its holdings in shares of Moderna, Inc. (NASDAQ:MRNA) by 1.5% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 43,883 shares of the company’s stock after selling 685 shares during the quarter. State of Alaska Department of Revenue’s holdings in Moderna were worth $1,824,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Yousif Capital Management LLC lifted its position in Moderna by 3.9% during the fourth quarter. Yousif Capital Management LLC now owns 42,171 shares of the company’s stock valued at $1,753,000 after purchasing an additional 1,568 shares in the last quarter. abrdn plc lifted its position in shares of Moderna by 28.1% during the 4th quarter. abrdn plc now owns 315,912 shares of the company’s stock valued at $12,842,000 after buying an additional 69,360 shares in the last quarter. McAdam LLC lifted its position in shares of Moderna by 5.0% during the 4th quarter. McAdam LLC now owns 11,768 shares of the company’s stock valued at $489,000 after buying an additional 562 shares in the last quarter. Greenleaf Trust grew its stake in shares of Moderna by 49.6% during the 4th quarter. Greenleaf Trust now owns 5,244 shares of the company’s stock valued at $218,000 after acquiring an additional 1,739 shares during the period. Finally, Spire Wealth Management increased its holdings in Moderna by 2,150.4% in the 4th quarter. Spire Wealth Management now owns 23,224 shares of the company’s stock worth $966,000 after acquiring an additional 22,192 shares in the last quarter. 75.33% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Moderna

In other news, insider Shannon Thyme Klinger sold 1,418 shares of the company’s stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $42.79, for a total value of $60,676.22. Following the completion of the sale, the insider now owns 19,717 shares of the company’s stock, valued at approximately $843,690.43. This represents a 6.71 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders sold a total of 2,664 shares of company stock worth $115,210 in the last quarter. 15.20% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on MRNA shares. Hsbc Global Res raised shares of Moderna from a “hold” rating to a “strong-buy” rating in a report on Monday, November 18th. Morgan Stanley dropped their price objective on Moderna from $70.00 to $38.00 and set an “equal weight” rating for the company in a research note on Wednesday, January 15th. Jefferies Financial Group dropped their price target on Moderna from $65.00 to $55.00 and set a “hold” rating for the company in a research note on Tuesday, October 15th. Sanford C. Bernstein initiated coverage on shares of Moderna in a report on Thursday, October 17th. They issued a “market perform” rating and a $55.00 price target on the stock. Finally, Wolfe Research initiated coverage on shares of Moderna in a report on Friday, November 15th. They set an “underperform” rating and a $40.00 price objective for the company. Four research analysts have rated the stock with a sell rating, fourteen have given a hold rating, four have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Moderna currently has an average rating of “Hold” and a consensus target price of $66.89.

Moderna Trading Down 2.9 %

MRNA opened at $30.93 on Wednesday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.20 and a current ratio of 4.39. The stock’s 50 day moving average price is $39.77 and its 200-day moving average price is $56.76. Moderna, Inc. has a one year low of $30.70 and a one year high of $170.47. The stock has a market cap of $11.90 billion, a price-to-earnings ratio of -5.31 and a beta of 1.59.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.